1998•PubMedRequires access

[Clinical study on qiangxinling liquid extract in treating congestive heart failure].

Han‐Yu Lin, C Wang, Wei Li Guo

Open publisher page 0 citations

Abstract

OBJECTIVE: To find the safe and effective treatment and drugs for congestive heart failure (CHF). METHODS: Ninety CHF patients whose heart function belong to III-IV grade were randomly divided into 3 groups: Group A was treated with Qiangxinling liquid extract (QXLLE); Group B with QXLLE plus small dose of digoxin and Group C with digoxin alone. RESULTS: The total effective rate on heart function of Group A was 86.7%, Group B 93.3% and Group C 83.3%, the effect of Group B was better than that of the other two groups (P < 0.05, P < 0.01). The digoxin withdrawing and reducing rate in Group B was higher than that in Group C (86.7% vs 50.0%, P < 0.05). The left ventricular systolic function, including stroke volume, cardiac output, ejection fraction of the 3 groups were improved after treatment, among them the effect of Group B was the best (P < 0.01). Moreover, improvement in ventricular diastolic function was shown in Group A and B, including the maximum blood flow of the late and the early diastolic stage as well as the ratio of them (P < 0.05, P < 0.01). The plasma renin activity, angiotensin II and atrial natriuretic peptide of Group A and B were also lowered after treatment and were significantly different to those of the Group C (P < 0.01). CONCLUSIONS: QXLLE could improve the heart function, clinical symptoms and neuro-endocrinal indexes of CHF patients and reduce the side effects of digoxin.

About this research paper

What this paper is about

OBJECTIVE: To find the safe and effective treatment and drugs for congestive heart failure (CHF). METHODS: Ninety CHF patients whose heart function belong to III-IV grade were randomly divided into 3 groups: Group A was treated with Qiangxinling liquid extract (QXLLE); Group B with QXLLE plus small dose of digoxin and Group C with digoxin alone. RESULTS: The total effective rate on heart function of Group A was 86.7%, Group B 93.3% and Group C 83.3%, the effect of Group B was better than that of the other two groups (P < 0.05, P < 0.01). The digoxin withdrawing and reducing rate in Group B was higher than that in Group C (86.7% vs 50.0%, P < 0.05). The left ventricular systolic function, including stroke volume, cardiac output, ejection fraction of the 3 groups were improved after treatment, among them the effect of Group B was the best (P < 0.01). Moreover, improvement in ventricular diastolic function was shown in Group A and B, including the maximum blood flow of the late and the early diastolic stage as well as the ratio of them (P < 0.05, P < 0.01). The plasma renin activity, angiotensin II and atrial natriuretic peptide of Group A and B were also lowered after treatment and were significantly different to those of the Group C (P < 0.01). CONCLUSIONS: QXLLE could improve the heart function, clinical symptoms and neuro-endocrinal indexes of CHF patients and reduce the side effects of digoxin.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: To find the safe and effective treatment and drugs for congestive heart failure (CHF). METHODS: Ninety CHF patients whose heart function belong to III-IV grade were randomly divided into 3 groups: Group A was treated with Qiangxinling liquid extract (QXLLE); Group B with QXLLE plus small dose of digoxin and Group C with digoxin alone. RESULTS: The total effective rate on heart function of Group A was 86.7%, Group B 93.3% and Group C 83.3%, the effect of Group B was better than that of the other two groups (P < 0.05, P < 0.01). The digoxin withdrawing and reducing rate in Group B was higher than that in Group C (86.7% vs 50.0%, P < 0.05). The left ventricular systolic function, including stroke volume, cardiac output, ejection fraction of the 3 groups were improved after treatment, among them the effect of Group B was the best (P < 0.01). Moreover, improvement in ventricular diastolic function was shown in Group A and B, including the maximum blood flow of the late and the early diastolic stage as well as the ratio of them (P < 0.05, P < 0.01). The plasma renin activity, angiotensin II and atrial natriuretic peptide of Group A and B were also lowered after treatment and were significantly different to those of the Group C (P < 0.01). CONCLUSIONS: QXLLE could improve the heart function, clinical symptoms and neuro-endocrinal indexes of CHF patients and reduce the side effects of digoxin.

Key concepts: Digoxin, Ejection fraction, Heart failure, Medicine, Group B, Internal medicine, Cardiology, Cardiac function curve

Related papers

Back to paper searchBrowse research topicsOriginal source
[Clinical study on qiangxinling liquid extract in treating congestive heart failure]. — Research Paper | ScholarLens